Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Breastfeeding infants with phenylketonuria in the United States and Canada.
[phenylketonuria]
This
study
described
the
prevalence
and
duration
of
mothers
'
breastfeeding
infants
with
phenylketonuria
(
PKU
)
and
explored
factors
related
to
duration
of
breastfeeding
as
a
surrogate
for
breastfeeding
success
.
Descriptive
analysis
as
performed
from
an
international
Internet
survey
of
mothers
(
n
=
103
)
who
met
the
inclusion
criteria
:
(
1
)
at
least
21
years
of
age
,
(
2
)
able
to
read
and
write
in
English
,
(
3
)
child
with
PKU
,
and
(
4
)
living
in
the
United
States
or
Canada
.
Of
the
103
mothers
,
89
(
86
%
)
initiated
breastfeeding
immediately
following
delivery
,
whereas
14
(
14
%
)
chose
bottle
feeding
.
In
comparison
to
breastfeeding
after
delivery
,
significantly
fewer
mothers
breastfed
after
diagnosis
(
McNemar
's
χ
(
2
)
=
30
.
33
,
p
<
0
.
001
;
n
=
72
vs
.
n
=
89
)
.
Breastfeeding
duration
ranged
from
less
than
1
month
to
24
months
with
one
modal
duration
category
(
n
=
20
,
22
%
)
at
less
than
1
month
.
The
timing
of
the
addition
of
commercial
infant
formula
to
supplement
breastfeeding
or
expressed
mothers
'
milk
was
associated
with
a
shorter
duration
of
breastfeeding
among
infants
with
PKU
:
χ
(
2
)
(
42
,
n
=
73
)
=
88
.
13
,
p
<
0
.
001
.
PKU
is
treated
with
phenylalanine
(
Phe
)
restriction
.
Breastfeeding
infants
with
PKU
is
challenging
in
part
because
Phe
intake
is
difficult
to
determine
precisely
.
We
studied
breastfeeding
duration
in
infants
with
PKU
and
factors
associated
with
success
.
Further
research
should
identify
the
unique
needs
of
mothers
'
breastfeeding
infants
with
PKU
to
guide
the
development
of
interventions
specific
to
these
mothers
to
support
their
efforts
to
continue
breastfeeding
after
the
diagnosis
of
PKU
.
Diseases
Validation
Diseases presenting
"further research"
symptom
22q11.2 deletion syndrome
achondroplasia
canavan disease
child syndrome
esophageal adenocarcinoma
harlequin ichthyosis
heparin-induced thrombocytopenia
inclusion body myositis
junctional epidermolysis bullosa
legionellosis
neuralgic amyotrophy
oculocutaneous albinism
phenylketonuria
waldenström macroglobulinemia
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom